In vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Abstract
The tau tangle ligand (18)F-AV-1451 ((18)F-T807) binds to neuromelanin in the midbrain, and may therefore be a measure of the pigmented dopaminergic neuronal count in the substantia nigra. Parkinson's disease is characterized by progressive loss of dopaminergic neurons. Extrapolation of post-mortem data predicts that a ∼30% decline of nigral dopamine neurons is necessary to cause motor symptoms in Parkinson's disease. Putamen dopamine terminal loss at disease onset most likely exceeds that of the nigral cell bodies and has been estimated to be of the order of 50-70%. We investigated the utility of (18)F-AV-1451 positron emission tomography to visualize the concentration of nigral neuromelanin in Parkinson's disease and correlated the findings to dopamine transporter density, measured by (123)I-FP-CIT single photon emission computed tomography. A total of 17 patients with idiopathic Parkinson's disease and 16 age- and sex-matched control subjects had (18)F-AV-1451 positron emission tomography using a Siemens high-resolution research tomograph. Twelve patients with Parkinson's disease also received a standardized (123)I-FP-CIT single photon emission computed tomography scan at our imaging facility. Many of the patients with Parkinson's disease displayed visually apparent decreased (18)F-AV-1451 signal in the midbrain. On quantitation, patients showed a 30% mean decrease in total nigral (18)F-AV-1451 volume of distribution compared with controls (P = 0.004), but there was an overlap of the individual ranges. We saw no significant correlation between symptom dominant side and contralateral nigral volume of distribution. There was no correlation between nigral (18)F-AV-1451 volume of distribution and age or time since diagnosis. In the subset of 12 patients, who also had a (123)I-FP-CIT scan, the mean total striatal dopamine transporter signal was decreased by 45% and the mean total (18)F-AV-1451 substantia nigra volume of distribution was decreased by 33% after median disease duration of 4.7 years (0.5-12.4 years). (18)F-AV-1451 positron emission tomography may be the first radiotracer to reflect the loss of pigmented neurons in the substantia nigra of parkinsonian patients. The magnitude of the nigral signal loss was smaller than the decrease in striatal dopamine transporter signal measured by dopamine transporter single photon emission computed tomography. These findings suggest a more severe loss of striatal nerve terminal function compared with neuronal cell bodies, in accordance with the post-mortem literature.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Off-target binding cannot fully account for [18F]AV-1451 signal in the striatum or cortex, nor in the choroid plexus.
“However, ‘off-target’ binding can neither fully account for [18F]AV-1451 signal in striatum or cortex – as previous post mortem analyses reveal that no neuromelanin accumulates there8,33 – nor in choroid plexus as histological analysis revealed tangle-like inclusions in its epithelial cells34.”
From Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy (2020) · cites this paper as [33]
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025 · see citing works
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · see citing works
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653 · see citing works
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · see citing works
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · see citing works
Hummel, T., Sekinger, B., Wolf, S. R., Pauli, E., & Kobal, G. (1997) · Chemical Senses · doi:10.1093/chemse/22.1.39 · Cited by 2,501 · see citing works
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,041 · see citing works
The substantia nigra of the human brain
Damier, P., Hirsch, É. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,772 · see citing works
Goetz, C. G., Fahn, S., Martínez‐Martín, P., Poewe, W. H., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R. C., Dubois, B., et al. (2006) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404 · see citing works
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 2× · see citing works
“This distinction is important, since pigmented and non-pigmented neurons may display differential susceptibility to neurodegeneration in Parkinson’s disease, as has been demonstrated by several authors (Hirsch et al., 1988; Zucca et al., 2014).”
BackgroundResultDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,294 · see citing works
Hammers, A., Allom, R. J., Koepp, M. J., Free, S. L., Myers, R., Lemieux, L., Mitchell, T. N., Brooks, D. J., & Duncan, J. S. (2003) · Human Brain Mapping · doi:10.1002/hbm.10123 · Cited by 1,270 · see citing works
Self-citationClinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · see citing works
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807 · see citing works
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
Killiany, R., Gómez‐Isla, T., Moss, M. B., Kikinis, R., Sándor, T., Jolesz, F. A., Tanzi, R. E., Jones, K. J., Hyman, B. T., & Albert, M. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4 · Cited by 659 · see citing works
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
Time course of nigrostriatal degeneration in parkinson's disease
Riederer, P. F., & Wuketich, S. (1976) · Journal of Neural Transmission · doi:10.1007/bf01249445 · Cited by 577 · see citing works
Gibb, W. R. G., & Lees, A. J. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574 · see citing works
Morrish, P., Rakshi, J. S., Bailey, D. L., Sawle, G. V., & Brooks, D. J. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.314 · Cited by 509 · see citing works
Self-citationSasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., Takahashi, S., Ehara, S., Terayama, Y., & Sakai, A. (2006) · Neuroreport · doi:10.1097/01.wnr.0000227984.84927.a7 · Cited by 496 · see citing works
Pakkenberg, B., Møller, A., Gundersen, H. J. G., Dam, A. M., & Pakkenberg, H. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.1.30 · Cited by 408 · see citing works
Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K. F., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396 · see citing works
MARSDEN, C. D. (1990) · The Lancet · doi:10.1016/0140-6736(90)91006-v · Cited by 363 · see citing works
Greffard, S., Verny, M., Bonnet, A.-M., Beinis, J., Gallinari, C., Meaume, S., Piette, F., Hauw, J., & Duyckaerts, C. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.584 · Cited by 355 · see citing works
Striatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy-Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 284 · see citing works
Rakshi, J. S., Uema, T., Ito, K., Bailey, D. L., Morrish, P., Ashburner, J., Dagher, A., Jenkins, I. H., Friston, K. J., & Brooks, D. J. (1999) · Brain · doi:10.1093/brain/122.9.1637 · Cited by 269 · see citing works
Self-citationPositron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albin, R. L., Koeppe, R. A., Wernette, K., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254 · see citing works
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243 · see citing works
Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808768105 · Cited by 240 · see citing works
Kästner, A., Hirsch, É. C., Lejeune, O., Javoy-Agid, F., Rascol, O., & Agid, Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08350.x · Cited by 228 · see citing works
Longitudinal changes in free-water within the substantia nigra of Parkinson’s disease
Ofori, E., Pasternak, O., Planetta, P. J., Li, H., Burciu, R. G., Snyder, A. F., Lai, S., Okun, M. S., & Vaillancourt, D. E. (2015) · Brain · doi:10.1093/brain/awv136 · Cited by 222 · see citing works
Possible role of neuromelanin in the pathogenesis of Parkinson's disease
Mann, D. M. A., & Yates, P. O. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90074-x · Cited by 211 · see citing works
Bajaj, N. P. S., Hauser, R. A., & Grachev, I. D. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304436 · Cited by 207 · see citing works
T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease
Schwarz, S. T., Rittman, T., Gontu, V. K., Morgan, P. S., Bajaj, N. P. S., & Auer, D. P. (2011) · Movement Disorders · doi:10.1002/mds.23722 · Cited by 186 · see citing works
Stage‐dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease
Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Bank, N. B., Rozemüller, A. J. M., & van de Berg, W. D. J. (2014) · Movement Disorders · doi:10.1002/mds.25952 · Cited by 173 · see citing works
Ohtsuka, C., Sasaki, M., Konno, K., Koide, M., Kato, K., Takahashi, J., Takahashi, S., Kudo, K., Yamashita, F., & Terayama, Y. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.012 · Cited by 171 · see citing works
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012) · Neurology · doi:10.1212/wnl.0b013e318278fe32 · Cited by 163 · see citing works
Ma, S. Y., Röyttä, M., Rinne, J. O., Collan, Y. U., & Rinne, U. K. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00100-7 · Cited by 161 · see citing works
Gibb, W. R. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90719-p · Cited by 152 · see citing works
Tissingh, G., Booij, J., Bergmans, P., et al. (1998) · PubMed · Cited by 142 · see citing works
Comparison of 3-D reconstruction with 3D-OSEM and with FORE+OSEM for PET
Liu, X. E., Comtat, C., Michel, C. J., et al. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.938248 · Cited by 129 · see citing works
Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients
Reimão, S., Lobo, P. P., Neutel, D., et al. (2014) · European Journal of Neurology · doi:10.1111/ene.12613 · Cited by 105 · see citing works
Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT
Pirker, W., Holler, I., Gerschlager, W., et al. (2003) · Movement Disorders · doi:10.1002/mds.10531 · Cited by 94 · see citing works
Validation of nigrostriatal positron emission tomography measures: Critical limits
Karimi, M., Tian, L., Brown, C., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23798 · Cited by 90 · see citing works
Tyrosine hydroxylase and methionine-enkephalin in the human mesencephalon
Gaspar, P., Berger, B., Gay, M., Hamon, M., Cesselin, F., Vigny, A., Javoy-Agid, F., & Agid, Y. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90221-6 · Cited by 87 · see citing works
Histochemical observations on rodent brain melanin
Barden, H., & Levine, S. (1983) · Brain Research Bulletin · doi:10.1016/0361-9230(83)90218-6 · Cited by 87 · see citing works
Filippi, L., Manni, C., Pierantozzi, M., Brusa, L., Danieli, R., Stanzione, P., & Schillaci, O. (2005) · Nuclear Medicine Communications · doi:10.1097/00006231-200505000-00005 · Cited by 84 · see citing works
A concise radiosynthesis of the tau radiopharmaceutical, [18F]T807
Shoup, T. M., Yokell, D. L., Rice, P. A., Jackson, R. N., Livni, E., Johnson, K. A., Brady, T. J., & Vasdev, N. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3098 · Cited by 80 · see citing works
Metabolic rates in small brain nuclei determined by high-resolution PET.
Heiss, W., Habedank, B., Klein, J. C., Herholz, K., Wienhard, K., Lenox, M., & Nutt, R. (2004) · PubMed · Cited by 76 · see citing works
Ma, S. Y., Rinne, J. O., Collan, Y. U., Röyttä, M., & Rinne, U. K. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00069-x · Cited by 47 · see citing works
Kuya, K., Shinohara, Y., Miyoshi, F., et al. (2016) · Neuroradiology · doi:10.1007/s00234-016-1644-7 · Cited by 45 · see citing works
The substantia nigra pars compacta of the Göttingen minipig: an anatomical and stereological study
Nielsen, M. S., Sørensen, J. C. H., & Bjarkam, C. R. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0217-5 · Cited by 40 · see citing works
Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders
Borghammer, P., Knudsen, K., Østergaard, K., et al. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12445 · Cited by 19 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Schonhaut, D. R., McMillan, C. T., Spina, S., Dickerson, B. C., Siderowf, A., Devous, M. D., Tsai, R., Winer, J., Russell, D. S., Litvan, I., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25060 · Cited by 175 · see citing works
[<sup>18</sup>F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy
Whitwell, J. L., Lowe, V. J., Tosakulwong, N., Weigand, S. D., Senjem, M. L., Schwarz, C. G., Spychalla, A. J., Petersen, R. C., Jack, C. R., & Josephs, K. A. (2017) · Movement Disorders · doi:10.1002/mds.26834 · Cited by 159 · see citing works
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case.
Marquié, M., Verwer, E. E., Meltzer, A. C., Kim, S. J. W., Agüero, C., Gonzalez, J., Makaretz, S. J., Siao Tick Chong, M., Ramanan, P., Amaral, A. C., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0482-0 · Cited by 128 · see citing works
Subcortical <sup>18</sup>F‐AV‐1451 binding patterns in progressive supranuclear palsy
Cho, H., Choi, J. Y., Hwang, M. S., Lee, S. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2017) · Movement Disorders · doi:10.1002/mds.26844 · Cited by 119 · see citing works
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26813 · Cited by 118 · see citing works
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T. D., Arnold, R., Allinson, K. S. J., Coles, J. P., Aigbirhio, F. I., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316402 · Cited by 84 · see citing works
Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy
Malpetti, M., Passamonti, L., Rittman, T., Jones, P. S., Vázquez Rodríguez, P., Bevan‐Jones, W. R., Hong, Y. T., Fryer, T. D., Aigbirhio, F. I., O'Brien, J. T., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25911 · Cited by 83 · see citing works
Peet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74 · see citing works
[18F]‐THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy
Brendel, M., Schönecker, S., Höglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J., Rohrer, G., Zach, C., Vettermann, F., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00440 · Cited by 72 · see citing works
Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study
Parbo, P., Ismail, R., Sommerauer, M., Stokholm, M. G., Hansen, A. K., Hansen, K. V., Amidi, A., Schaldemose, J. L., Gottrup, H., Brændgaard, H., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.004 · Cited by 63 · see citing works
Self-citationTau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.
Smith, R., Schöll, M., Honer, M., Nilsson, C. F., Englund, E., & Hansson, O. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1650-1 · Cited by 62 · see citing works
Biomarkers for diseases with TDP-43 pathology
Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57 · see citing works
MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
Hansen, A. K., Brooks, D. J., & Borghammer, P. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1143-1 · Cited by 51 · see citing works
Self-citationCapucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T. (2021) · Antioxidants · doi:10.3390/antiox10060824 · Cited by 36 · see citing works
- Authors
- Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., & Borghammer, P.
- Affiliations
- Aarhus University Hospital (DK)
- Aarhus University (DK)
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-05
- Volume
- 139
- Issue
- 7
- Pages
- 2039-2049
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2346403897
- Cited by
- 128
- References
- 53
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 10 · 2022: 8 · 2021: 16 · 2020: 12 · 2019: 16 · 2018: 20 · 2017: 24 · 2016: 7
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Lundbeckfonden (R190-2014-4183)
- Avid Radiopharmaceuticals
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Parkinson's disease, neuromelanin, 18F-AV-1451, substantia nigra, dopaminergic neurons, dopamine transporter, 123I-FP-CIT, volume of distribution, tau pathology, striatum, disease duration, neurodegeneration
- MeSH terms
- Adult, Aged, Aged, 80 and over, Corpus Striatum, Female, Fluorine Radioisotopes, Humans, Male, Melanins, Middle Aged, Parkinson Disease, Substantia Nigra, Time Factors, Tropanes, Biomarkers, Tomography, Emission-Computed, Single-Photon, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
